Omkar Speciality Chemicals exits CIRP: FY26 Q3 update

Omkar Speciality Chemicals Limited has formally transitioned out of the Corporate Insolvency Resolution Process (CIRP) after the National Company Law Tribunal (NCLT) approved its resolution plan on July 31, 2025. The company has since published unaudited financial results for the first three quarters of FY 2025-26, covering quarters ended June 30, 2025, September 30, 2025, and December 31, 2025.

The disclosures matter because they provide an early look at operations under the post-resolution structure. They also highlight a key contrast for investors tracking the turnaround: debt has been significantly reduced post-resolution, but the company still reports no revenue from operations and continues to post quarterly losses.

What changed after NCLT approval

The NCLT order approving the resolution plan on July 31, 2025 marked the company’s exit from CIRP. The quarterly numbers disclosed for FY26 Q1 to Q3 are positioned as results released after the approval and under a new management structure.

The company’s update ties these quarterly results to the post-resolution phase, suggesting stakeholders should read the figures as an early operating snapshot after the transition. At the same time, the published risk factors in the update are clear: the turnaround depends on restarting or scaling operations, while execution of strategic initiatives around capital expenditure and working capital remains a critical requirement.

Unaudited results for FY26 Q1 to Q3

Omkar Speciality reported Revenue from Operations of ₹0 crore for FY 2025-26 across Q1 to Q3. For the same three quarters, the company disclosed net losses, indicating that costs continued even as operating revenue remained absent.

The disclosed quarterly net profit or loss figures are:

• FY26 Q1: ₹-0.41 crore
• FY26 Q2: ₹-0.52 crore
• FY26 Q3: ₹-0.33 crore

These numbers underline the immediate post-CIRP challenge: stabilising the business operationally rather than only through balance sheet restructuring. The “reader takeaway” provided alongside the update captures this directly, noting the sharp reduction in debt post-resolution but continued zero revenue and losses.

Monitoring Committee approval and reporting process

The company stated that its Monitoring Committee approved the unaudited financial results for Q1, Q2, and Q3 of FY26. The filings also reference the regulatory framework under which such periodic financial reporting is made, including Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The review report language included in the information notes that a review of interim financial information is more limited than a statutory audit. It refers to the Standard on Review Engagement (SRE) 2410, and states that the reviewer does not express an audit opinion.

Auditor’s qualified conclusion and going concern focus

A key watchpoint highlighted is the auditor’s qualified conclusion, particularly around the use of the going concern basis despite a negative net worth. The company’s risk section also flags the ongoing net losses and the inability to generate operating revenue as central risks.

This combination matters in a post-CIRP phase because even after a resolution plan is approved, market participants focus on whether the entity can operate sustainably. The update explicitly points to successful execution of strategic initiatives for capital expenditure and working capital as a requirement.

Management and board appointments post-CIRP

Alongside the financial disclosures, the company announced changes to leadership and governance as part of the post-resolution structure:

• Mr. Dipak Kumar Shaw was appointed as the Chief Executive Officer (CEO).
• Mr. Ruhini Kumar Chakraborty was appointed as an Independent Director.

These appointments form part of the governance reset typically expected after a CIRP exit, when new oversight and operational leadership are expected to align execution with the approved resolution plan.

Statutory auditor appointment for FY 2025-26

Omkar Speciality Chemicals also disclosed the appointment of R. R. Tibrewala & Co. as its Statutory Auditor for FY 2025-26. The company described the appointment as filling a casual vacancy and formalising governance structures post-CIRP.

The disclosure references an exchange filing under Regulation 30 (LODR), which covers material events and information that listed entities must disclose.

Share price snapshot and market context

The update includes a market datapoint: Omkar Speciality Chemicals share price was ₹3.6 as of 4 Jun, 2026. This provides context on where the stock traded after the CIRP exit and subsequent quarterly disclosures.

Separately, the provided material also includes a prior price reference showing 7.49 as the close on Jun 16, 2025 (delayed price, INR). The two datapoints together indicate that the stock traded at different levels across the pre- and post-resolution timeline, though the company’s FY26 operating revenue for Q1 to Q3 remained at zero.

Additional financial tables present in the disclosures

The provided information also contains financial tables listing quarterly revenue and profitability figures in crores, including values such as Total Qtr Revenue (₹ crore): 126.70, 130.03, 113.37, 113.86, 108.66 and quarterly net profit values like 10.51, 11.56, 10.97, 4.03, 9.40. These figures appear as part of an “Annual and Quarterly P/L, Balance Sheet, Cash Flow & Financial Ratios” section, but the specific mapping of these columns to financial years or quarters is not stated in the text.

Another table is labelled as an income statement with financials in million INR and includes Total Revenues: 1,915.87 million INR, which normalises to ₹191.587 crore (since 10 million INR equals ₹1 crore). The same table also lists Total Revenues: 426.52, 568.77, 451.25, 229.83 million INR, which normalise to ₹42.652 crore, ₹56.877 crore, ₹45.125 crore, and ₹22.983 crore respectively.

Key facts at a glance

Why these disclosures matter for investors

The post-CIRP updates put two issues side by side. On one hand, the company’s communication points to a meaningful reduction in debt following the resolution. On the other, the FY26 Q1 to Q3 disclosures show no operating revenue and continuing quarterly losses, which keeps the focus on whether operations can restart at scale.

The auditor’s qualified conclusion around going concern, coupled with the note on negative net worth, is another factor that investors typically track closely in post-resolution cases. The company itself has flagged execution of capex and working capital initiatives as a key risk, suggesting that operational stabilisation is central to the next phase.

Conclusion

Omkar Speciality Chemicals’ exit from CIRP following the NCLT approval on July 31, 2025 is now reflected in its post-resolution reporting and governance changes, including new leadership appointments and a statutory auditor for FY 2025-26. But the FY26 Q1 to Q3 unaudited numbers show ₹0 crore revenue from operations and net losses each quarter. The next set of disclosures and updates on execution of the resolution plan’s operational initiatives will remain the primary markers to watch.